HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA NDI Draft Is A Push For Tighter Supplement Regulation – Stakeholders

This article was originally published in The Tan Sheet

Executive Summary

FDA proposed “a pretty crazy” NDI notification draft guidance, says attorney Wes Siegner, because “they think everything is an NDI.” Other stakeholders acknowledge FDA wants tighter regulation of the industry, but say writing and imposing rules for supplement manufacturing is a two-way street.

You may also be interested in...



In Brief: Acetaminophen Warnings, OTC HSA Bill, Durbin’s Supplement Reg Bill

FDA adds acetaminophen warnings; CHPA suggests 4-aminophenol standard; OTC HSA bill in House; supplement registration bill reintroduced; FSMA user fees still on hold; more scrutiny of energy drinks; and Public Citizen pans OTC Oxytrol.

Consent Decrees Are Last “Dance” For Supplement GMP Violators

Consent decrees allow time for a firm to make changes with the goal of re-opening, but not without costly updates to systems and equipment and retaining a consultant and attorneys, food and drug attorney Tony Young says.

McCain-Dorgan NDI Guidance, Steroid Provisions In Senate Food Safety Bill

Requirements that benefit dietary supplement manufacturing and that gained Sen. John McCain's support after he initially proposed legislation considered a threat to the industry are part of the food safety reform bill pending in the Senate.

Topics

Latest News
See All
UsernamePublicRestriction

Register

RS124348

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel